This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
31 Jan 2012

FDA Approves Jentadueto Tablets for Type 2 Diabetes

FDA has approved Jentadueto tablets for patients who need to control their blood sugar.

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced Monday that the FDA has approved Jentadueto (linagliptin/metformin hydrochloride) tablets for patients who need to control their blood sugar. 

 

Jentadueto is a prescription medication used along with diet and exercise to improve glycemic control in adults with type 2 diabetes when treatment with both linagliptin and metformin is appropriate.

 

Jentadueto can be used alone or in combination with a sulfonylurea, a commonly prescribed medication for type 2 diabetes. Jentadueto is not for the treatment of type 1 diabetes or diabetic ketoacidosis (increased ketones in the blood or urine). It has not been studied in combination with insulin.

 <

Related News